Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 19/20 | 0.62 |
| ▸ | BCR | P11274 | 13/20 | 0.62 |
| ▸ | LYN | P07948 | 4/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.61 |
| ▸ | EGFR | P00533 | 2/20 | 0.61 |
| ▸ | PRKCA | P17252 | 1/20 | 0.61 |
| ▸ | KIT | P10721 | 6/20 | 0.60 |
| ▸ | KDR | P35968 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | SLC22A3 | O75751 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | RAF1 | P04049 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 2/20 | 0.60 |
| ▸ | FYN | P06241 | 2/20 | 0.60 |
| ▸ | CSF1R | P07333 | 2/20 | 0.60 |
| ▸ | CA3 | P07451 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | FGR | P09769 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29552050 | 1.00 | ABL1 (0.62) | ABL1BCRLYNPDGFRBPDGFRA | |
| SCHEMBL24251074 | 0.96 | ABL1 (0.61) | ABL1BCRLYNPDGFRBPDGFRA | |
| SCHEMBL29551050 | 0.96 | ABL1 (0.61) | ABL1BCRLYNPDGFRBPDGFRA | |
| SCHEMBL29551452 | 0.96 | ABL1 (0.66) | ABL1BCRLYNPDGFRBPDGFRA | |
| SCHEMBL24251077 | 0.96 | ABL1 (0.66) | ABL1BCRLYNPDGFRBPDGFRA | |
| SCHEMBL24250933 | 0.91 | ABL1 (0.71) | ABL1BCRLYNPDGFRBPDGFRA | |
| SCHEMBL29551282 | 0.91 | ABL1 (0.71) | ABL1BCRLYNPDGFRBPDGFRA | |
| SCHEMBL24250979 | 0.88 | ABL1 (0.64) | ABL1BCRLYNPDGFRBKIT | |
| SCHEMBL29551609 | 0.88 | ABL1 (0.64) | ABL1BCRLYNPDGFRBKIT | |
| SCHEMBL24250899 | 0.88 | ABL1 (0.65) | ABL1BCRLYNPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114127065-A | Compounds for the treatment of neurodegenerative diseases and cancer | 鸿仪有限责任公司 | 2022-03-01 | — | — | CN | claimed |
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | HONGYI & ASS LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | SNCA, NGF, SLC18A2 | ABL1 695/4885BCR 1219/4885LYN 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.